Skip to main content

Technology Transfer

Team Responsible for the Technology Showcase Receives NCI Director’s Award

A broadly based team from Frederick National Laboratory (FNL), NCI’s Technology Transfer Center, and NCI’s Office of Scientific Operations has been recognized with a 2020 NCI Director’s Award. The award, from the “Making an Impact” category, recognizes the team’s work to establish the annual Technology Showcase, an event that fosters scientific collaboration as well as licensing of NCI technologies.

Technology Showcase 2020 Goes Virtual

The fourth annual Technology Showcase is making a big pivot this year, moving to an entirely virtual event on September 9, 2020. Although the move was made out of necessity, it also offers exciting new opportunities to reach more partners and licensees beyond Frederick, Md.

2019 Technology Showcase Highlights Technologies, Partnerships—and Frederick

Frederick has become a key player in biomedical research. That was the clear message from the third annual Technology Showcase, hosted by the National Cancer Institute (NCI) and the Frederick National Laboratory for Cancer Research. As usual, the event highlighted the numerous technologies developed by NCI and FNL scientists that are available to external groups for licensing and partnership. But this year, it also showcased the strength of the region.

Annual Event Connects NCI and FNL Technologies with Potential Partners

Next month, the annual Technology Showcase will return to the Frederick National Laboratory for Cancer Research. The event attracts research innovators and business professionals who wish to learn about advanced technologies being developed at the National Cancer Institute and Frederick National Laboratory.

Inaugural Technology Showcase Draws Hundreds

Before a crowded auditorium of science and business professionals at the Frederick National Laboratory for Cancer Research’s Advanced Technology Research Facility (ATRF), Joost Oppenheim, M.D., had just finished his presentation about a compound with the potential to expand the impact of a promising category of cancer therapeutics when he fielded a question from Stephan Stern, Ph.D.